Maze Therapeutics (MAZE) Total Liabilities (2024 - 2026)

Maze Therapeutics has reported Total Liabilities for 3 years, with the latest figure at $78.0 million in Q1 2026.

• Quarterly Total Liabilities rose 91.33% year-over-year to $78.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.0 million (up 91.33% YoY) and the FY2025 annual result came in at $42.2 million, down 3.38% from the prior year.
• Total Liabilities climbed to $78.0 million in Q1 2026 per MAZE's latest filing, from $42.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $78.0 million in Q1 2026 and troughed at $40.8 million in Q1 2025.
• A 3-year average of $48.1 million and a median of $42.4 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities fell 3.38% in 2025, then jumped 91.33% in 2026.
• Over 3 years, Total Liabilities stood at $43.6 million in 2024, then slipped by 3.38% to $42.2 million in 2025, then surged by 85.03% to $78.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $78.0 million, $42.2 million, and $42.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.